These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

98 related items for PubMed ID: 1206996

  • 21. [Should lipid-lowering drugs be administered to normolipemic or mild hyperlipemic patients with coronary risk factors? Arguments for].
    de Teresa Galván E, Jiménez Navarro M.
    Rev Esp Cardiol; 1996 Jul; 49(7):483-5. PubMed ID: 8754441
    [No Abstract] [Full Text] [Related]

  • 22. [Secondary prevention of coronary artery disease with lipid-lowering drugs].
    Delahaye F, De Gevigney G.
    Ann Med Interne (Paris); 2001 Apr; 152(3):184-7. PubMed ID: 11431578
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Therapy and clinical trials.
    Curr Opin Lipidol; 1995 Dec; 6(6):B77-82. PubMed ID: 8750254
    [No Abstract] [Full Text] [Related]

  • 25. When to treat raised lipids.
    Jolleys J.
    Practitioner; 1999 Jun; 243(1599):510-3, 515-6. PubMed ID: 10476570
    [No Abstract] [Full Text] [Related]

  • 26. [Should lipid-lowering drugs be administered to normolipemic or mild hyperlipemic patients with coronary risk factors? Arguments against].
    Brotons Cuixart C, Maiques Galán A.
    Rev Esp Cardiol; 1996 Jul; 49(7):486-91. PubMed ID: 8754442
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Dietary and pharmacologic therapy of the lipid risk factors. AMA Council on Scientific Affairs.
    Conn Med; 1985 May; 49(5):321-8. PubMed ID: 3891221
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Warfarin metabolism during ethyl chlorophenoxyisobutyrate treatment.
    Pyörälä K, Ristola P, Myllylä G.
    Ann Med Intern Fenn; 1968 May; 57(4):157-60. PubMed ID: 5731345
    [No Abstract] [Full Text] [Related]

  • 35. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE.
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.